Format

Send to

Choose Destination
Jpn J Clin Oncol. 2016 Apr;46(4):389-92. doi: 10.1093/jjco/hyv211. Epub 2016 Jan 31.

Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study.

Author information

1
Cancer Center, Keio University School of Medicine, Tokyo yhamamoto@z2.keio.jp.
2
Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, Tokyo.
3
Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo.
4
Esophageal Surgical Division, Shizuoka Cancer Center, Shunto-gun.
5
Department of Radiology, Koshigaya Municipal Hospital, Koshigaya.
6
Esophageal Surgical Division, National Cancer Center Hospital, Tokyo.
7
Department of Thoracic Surgery, Aichi Cancer Center, Nagoya.
8
Department of Surgery, Keio University School of Medicine, Tokyo.
9
International Goodwill Hospital, Yokohama, Japan.

Abstract

It is important to examine variation in the treatment effects of patients with esophageal cancer in order to generalize treatment outcomes. We aimed to investigate the range of prognostic differences among hospitals in the treatment of locally advanced esophageal cancer. The JCOG0303 study compared the efficacy of radiotherapy plus low-dose cisplatin and 5-fluorouracil with that of high-dose cisplatin and 5-fluorouracil for unresectable esophageal cancer. Of 32 institutions participating in the JCOG0303 study, the 18 institutions that enrolled three or more patients were included in this study. We predicted the 1-year survival in each institution by using a mixed-effect model. We found that the predicted 1-year survival in the 18 institutions with three or more patients was a median of 60.9%, with a range of 60.9-60.9%. This study is the first to investigated heterogeneity of survival in patients who received definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

KEYWORDS:

chemoradiotherapy; esophageal cancer; heterogeneity

PMID:
26830150
PMCID:
PMC4886135
DOI:
10.1093/jjco/hyv211
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center